Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IDT Acquires SURVEYOR® Nuclease Business from Transgenomic

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.

Integrated DNA Technologies (IDT) has acquired the SURVEYOR® enzyme business of Transgenomic, Inc.  As part of the agreement with Transgenomic, IDT will acquire the SURVEYOR product line and intellectual property. Transgenomic will receive an exclusive license for clinical and diagnostic use of SURVEYOR products from IDT. Additional terms of the acquisition were not disclosed.

The key component of SURVEYOR products is SURVEYOR Nuclease, a member of the CEL nuclease family of mismatch-specific nucleases isolated from celery. SURVEYOR Nuclease has been shown to recognize and cleave mismatches arising from single nucleotide polymorphisms or small insertions or deletions.

The SURVEYOR Mutation Detection Kits provide a simple and robust method for detecting mutations and polymorphisms in DNA. IDT will sell SURVEYOR Mutation Detection Kits for both gel electrophoresis analysis and use on Transgenomic’s WAVE and WAVE HS systems. Transgenomic will continue to sell and support the WAVE and WAVE HS systems.

In addition to mutation detection, SURVEYOR Mutation Detection has emerged as the method of choice for verifying the outcome of genome editing by zinc finger nucleases, TALENs, CRISPR/Cas9 systems, and other emergent technologies. Genome editing is a mechanism of genetic engineering that employs “molecular scissors” to modify sections of DNA within a genome. These technologies are being investigated for use in excising defective regions within a genome and replacing them with the correct, desired sequences. The most recent of the technologies, clustered regulatory interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) systems, which occur naturally in lower organisms, are being manipulated to provide a flexible, specific, and relatively easy means of modifying mammalian genomes. Scientists are developing CRISPR/Cas9 systems for use in the clinic with the hope that millions of people can finally be cured of genetic disease.

Stephen Gunstream, Chief Commercial Officer at IDT, said of the acquisition, “We are excited about adding the SURVEYOR product line to our growing molecular biology portfolio. These products will be of great benefit to IDT customers, most of whom are in the field of genetic analysis, and of particular use to those whose work involves mutation detection or validation of CRISPR/Cas9 genome editing. IDT can offer these products with the same speed, quality, and support for which we have become known. We plan to continue developing and commercializing further applications of SURVEYOR Nuclease.”

Paul Kinnon, President and Chief Executive Officer of Transgenomic, commented, “The sale of our SURVEYOR Nuclease technology and assets for the research market to IDT allows us to focus more resources on our commercialization efforts in our core Patient Testing, Biomarker Identification, and Genetic Analysis and Platforms business units. By licensing back exclusive rights to clinical and diagnostic uses of the technology, we have ensured that we will have continued access to SURVEYOR technology in high value clinical and pharmaceutical services applications.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Untangling the Web of Gene Expression
New technology for understanding gene expression drives research forward.
Wednesday, May 20, 2015
Fast and Focused Sequencing from Single Genes to Entire Exomes
IDT reveals how to increase sequencing success with new and existing enrichment panels.
Monday, March 16, 2015
Discover Affordable Custom NGS Panels
IDT webinar helps NGS researchers bring cost-savings to target capture panels.
Thursday, February 12, 2015
Synthetic Biology Webinar - Genome Modifications Made Easy
IDT reveals how to overcome the challenges of CRISPR-mediated genome editing.
Thursday, January 15, 2015
IDT and Ubiquitome Partner to Develop Mobile Ebola Test
Handheld, battery-powered Freedom4 enables rapid field deployment of gold standard molecular test.
Wednesday, December 03, 2014
Discover the Latest NGS-Based Assays Guiding Precision Oncology
IDT joins forces with Foundation Medicine in AMP workshop.
Saturday, November 08, 2014
IDT Shares Tips for Optimizing Target Capture
The article discusses improved target capture methods for increasing reliability of next generation sequencing data.
Friday, October 24, 2014
From Honey Bees to Hearts - Keep Track of the Latest in NGS
Free IDT symposium explores diverse NGS applications.
Wednesday, September 24, 2014
Novel rhPCR Unravels Gene Expression
Method enables identification and analysis of highly similar alternatively spliced transcripts.
Tuesday, September 09, 2014
IDT Shares Comprehensive qPCR Resources
Special qPCR compendium issue of DECODED now freely available.
Wednesday, August 06, 2014
World Cup 2014 - with a Scientific Twist
IDT fuses fruit flies, football and fun in a unique global contest with great prizes.
Thursday, June 12, 2014
Summit Partners Makes Growth Equity Investment in IDT
IDT’s founder, Dr. Joseph Walder, will remain the company’s majority owner.
Wednesday, March 19, 2014
Enhanced Molecular Inversion Probes for NGS Target Enrichment
IDT presents latest developments at 15th annual Advances in Genome Biology and Technology meeting.
Tuesday, February 04, 2014
Not a Constant Value: Understanding Tm
IDT explains how to optimize oligo hybridization-based protocols.
Friday, December 20, 2013
Building 3D Nanostructures with Synthetic DNA
Harvard professor explains how to programme complex oligo structures for new applications.
Tuesday, December 10, 2013
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!